1-10 of 10
Laura K. Shawver
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3258: THOR-707, a novel not-alpha IL-2, elicits durable pharmacodynamic responses in non-human primates and efficacy as single agent and in combination with anti PD-1 in multiple syngeneic mouse models

Free
Ingrid B. Joseph, Lina Ma, Jerod L. Ptacin, Carolina E. Caffaro, Hans R. Aerni, Kristine M. San Jose, Michael J. Pena, Robert W. Herman, Yelena Pavlova, David B. Chen, Ken Bragstad, Shukuan Li, Jasmine Nguyen, Laura K. Shawver, Lilia K. Koriazova, Marcos E. Milla
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3258.
https://doi.org/10.1158/1538-7445.AM2019-3258
Published: 01 July 2019
View articletitled, Abstract 3258: THOR-707, a novel not-alpha IL-2, elicits durable pharmacodynamic responses in non-human primates and efficacy as single agent and in combination with anti PD-1 in multiple syngeneic mouse models
Journal Articles

Abstract 58: Differences in genomic alterations revealed by sequencing of 182 genes in recurrent ovarian cancer specimens compared to TCGA analysis: rearrangements in PTCH1 and FLT3; high frequency of RAS pathway alteration.

Free
Deborah A. Zajchowski, Doron Lipson, Gary Palmer, Laura K. Shawver
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 58.
https://doi.org/10.1158/1538-7445.AM2013-58
Published: 15 April 2013
View articletitled, Abstract 58: Differences in genomic alterations revealed by sequencing of 182 genes in recurrent ovarian cancer specimens compared to TCGA analysis: rearrangements in PTCH1 and FLT3; high frequency of RAS pathway alteration.
Journal Articles

Abstract 5077: Molecular profiling in recurrent ovarian cancer patients: Considerations for the design of clinical studies to validate profiling for therapy selection

Free
Deborah A. Zajchowski, Cory Bentley, Jenny Gross, Beth Y. Karlan, Laura K. Shawver
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 5077.
https://doi.org/10.1158/1538-7445.AM2011-5077
Published: 15 April 2011
View articletitled, Abstract 5077: Molecular profiling in recurrent ovarian cancer patients: Considerations for the design of clinical studies to validate profiling for therapy selection
Journal Articles

Abstract 809: Selecting ovarian cancer patients for clinical trials using a broad panel of molecular markers

Free
Deborah A. Zajchowski, Jenny Gross, Beth Y. Karlan, Ken Bloom, David Loesch, Eric Thompson, Arlet Alarcon, Laura K. Shawver
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 809.
https://doi.org/10.1158/1538-7445.AM10-809
Published: 15 April 2010
View articletitled, Abstract 809: Selecting ovarian cancer patients for clinical trials using a broad panel of molecular markers
Journal Articles

SU6668 Is a Potent Antiangiogenic and Antitumor Agent That Induces Regression of Established Tumors

Available to Purchase
A. Douglas Laird, Peter Vajkoczy, Laura K. Shawver, Andreas Thurnher, Congxin Liang, Moosa Mohammadi, Joseph Schlessinger, Axel Ullrich, Stevan R. Hubbard, Robert A. Blake, T. Annie T. Fong, Laurie M. Strawn, Li Sun, Cho Tang, Rachael Hawtin, Flora Tang, Narmada Shenoy, K. Peter Hirth, Gerald McMahon, Julie M. Cherrington
Journal: Cancer Research
Cancer Res (2000) 60 (15): 4152–4160.
Published: 01 August 2000
View articletitled, SU6668 Is a Potent Antiangiogenic and Antitumor Agent That Induces Regression of Established Tumors
Open the PDF for SU6668 Is a Potent Antiangiogenic and Antitumor Agent That Induces Regression of Established Tumors in another window
Journal Articles

SU5416 Is a Potent and Selective Inhibitor of the Vascular Endothelial Growth Factor Receptor (Flk-1/KDR) That Inhibits Tyrosine Kinase Catalysis, Tumor Vascularization, and Growth of Multiple Tumor Types

Available to Purchase
T. Annie T. Fong, Laura K. Shawver, Li Sun, Cho Tang, Harald App, T. Jeff Powell, Young H. Kim, Randall Schreck, Xueyan Wang, Werner Risau, Axel Ullrich, K. Peter Hirth, Gerald McMahon
Journal: Cancer Research
Cancer Res (1999) 59 (1): 99–106.
Published: 01 January 1999
View articletitled, SU5416 Is a Potent and Selective Inhibitor of the Vascular Endothelial Growth Factor Receptor (Flk-1/KDR) That Inhibits Tyrosine Kinase Catalysis, Tumor Vascularization, and Growth of Multiple Tumor Types
Open the PDF for SU5416 Is a Potent and Selective Inhibitor of the Vascular Endothelial Growth Factor Receptor (Flk-1/KDR) That Inhibits Tyrosine Kinase Catalysis, Tumor Vascularization, and Growth of Multiple Tumor Types in another window
Journal Articles

Flk-1 as a Target for Tumor Growth Inhibition

Available to Purchase
Laurie M. Strawn, Gerald McMahon, Harald App, Randall Schreck, William R. Kuchler, Michael P. Longhi, Terence H. Hui, Cho Tang, Alexander Levitzki, Aviv Gazit, Irit Chen, Gyorgy Keri, Laszlo Orfi, Werner Risau, Ingo Flamme, Axel Ullrich, K. Peter Hirth, Laura K. Shawver
Journal: Cancer Research
Cancer Res (1996) 56 (15): 3540–3545.
Published: 01 August 1996
View articletitled, Flk-1 as a Target for Tumor Growth Inhibition
Open the PDF for Flk-1 as a Target for Tumor Growth Inhibition in another window
Journal Articles

Dominant-Negative Inhibition of Flk-1 Suppresses the Growth of Many Tumor Types in Vivo

Available to Purchase
Birgit Millauer, Michael P. Longhi, Karl H. Plate, Laura K. Shawver, Werner Risau, Axel Ullrich, Laurie M. Strawn
Journal: Cancer Research
Cancer Res (1996) 56 (7): 1615–1620.
Published: 01 April 1996
View articletitled, Dominant-Negative Inhibition of Flk-1 Suppresses the Growth of Many Tumor Types in Vivo
Open the PDF for Dominant-Negative Inhibition of Flk-1 Suppresses the Growth of Many Tumor Types in Vivo in another window
Journal Articles

p185c-erbB-2 Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association between an Oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair

Available to Purchase
Carlos L. Arteaga, Angela R. Winnier, Miriam C. Poirier, Daniel M. Lopez-Larraza, Laura K. Shawver, Stephen D. Hurd, Stanford J. Stewart
Journal: Cancer Research
Cancer Res (1994) 54 (14): 3758–3765.
Published: 01 July 1994
View articletitled, p185c-erbB-2 Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association between an Oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair
Open the PDF for p185c-erbB-2 Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association between an Oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair in another window
Journal Articles

Ligand-like Effects Induced by Anti-c-erbB-2 Antibodies Do Not Correlate with and Are Not Required for Growth Inhibition of Human Carcinoma Cells

Available to Purchase
Laura K. Shawver, Elaina Mann, Susan S. Elliger, Teresa C. Dugger, Carlos L. Arteaga
Journal: Cancer Research
Cancer Res (1994) 54 (5): 1367–1373.
Published: 01 March 1994
View articletitled, Ligand-like Effects Induced by Anti-c-erbB-2 Antibodies Do Not Correlate with and Are Not Required for Growth Inhibition of Human Carcinoma Cells
Open the PDF for Ligand-like Effects Induced by Anti-c-erbB-2 Antibodies Do Not Correlate with and Are Not Required for Growth Inhibition of Human Carcinoma Cells in another window